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Background
The scale-up of interventions has re-
duced malaria burden and transmission
across a number of countries [1–3]. As
transmission declines, it often becomes
increasingly focal [4], and programs need
to adapt and target the remaining parasite
reservoirs, deploying resources with in-
creasing granularity. At very low trans-
mission intensity, elimination of malaria
may involve finding and treating individ-
ual infections.
At large spatial scales, infections tend to
cluster into foci related to environmental,
climatic, and ecological suitability for
vectors and transmission [5]. At smaller
scales within these foci, ‘‘hotspots’’, which
consist of a household or groups of
households, maintain higher transmission
of malaria and a consistent reservoir of
parasites throughout the year [4,6–8]
(Figure 1, Box 1). Infections are also
clustered in certain demographic ‘‘hot’’
populations, or ‘‘hotpops’’, associated with
demographic risk factors for transmission
[9–11] (Figure 2, Box 1). In low transmis-
sion or elimination settings, strategies for
detecting and targeting these clusters of
infection, whether geographic or demo-
graphic, become important strategies to
reduce the local parasite reservoir and
interrupt transmission [12].
All malaria control programs have
passive surveillance systems that, to great-
er or lesser degrees, identify, treat, and
report individuals with malaria who pres-
ent to health facilities. While useful for
intelligence gathering, passive surveillance
alone has a limited impact on malaria
transmission as only symptomatic patients
receive treatment when they seek medical
care. It is well known, however, that
whether transmission is low or high, the
majority of infections, including carriers of
gametocytes (the life parasite stage respon-
sible for onward transmission to mosqui-
toes), are asymptomatic [13–18].
To overcome the inherent limitations of
passive surveillance and to target the
asymptomatic parasite pool, as well as
symptomatic infections in individuals who
do not or cannot seek treatment, a number
of programs have adopted active case
detection (ACD) strategies [12]. Despite
its increasing popularity across a number
of countries, and recommendation by the
World Health Organization (WHO) for
use in malaria elimination [12], the
diversity of ACD methods and the relative
strengths and weaknesses of the various
approaches are poorly described. In this
Policy Forum, we discuss the potential role
of ACD in malaria control and elimina-
tion. While we focus on P. falciparum, the
discussion also includes the potential role
of ACD in the control and elimination of
P. vivax.
Active Case Detection Methods
ACD for malaria infection has a variety
of definitions and designs [19]. The WHO
recently revised the definition of ACD [12]
(Box 2) to differentiate methods that test
only febrile individuals (fever screening)
from those that target all individuals (active
infection detection, aggressive active case
detection, or mass screen and treat)
[14,20,21]. While requiring more resourc-
es, approaches that target all people at risk
of infection enable the targeting of the
asymptomatic parasite pool. For the re-
mainder of this discussion we use the term
ACD to refer to the active detection of
malaria infections in both symptomatically
and asymptomatically infected individuals.
The Policy Forum allows health policy makers
around the world to discuss challenges and
opportunities for improving health care in their
societies.
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Reactive Case Detection
Active case detection can be split into
two broad types: reactive (RACD) and
proactive (PACD) case detection (Table 1)
[22]. RACD takes advantage of the fact
that parasite carriage tends to be spatially
and temporally clustered. Therefore, in-
fections are found at higher prevalence in
households in close proximity to passively
detected cases [23].
Despite the widespread use of RACD, no
standardized guidelines have been estab-
lished on either the appropriate thresholds
to trigger its use or the screening radius to
use. A recent compilation of national
policies of countries participating in the
Asia Pacific Malaria Elimination Network
(APMEN), where P. vivax is the predomi-
nant malaria species, showed that programs
employ a wide range of different RACD
approaches [24]. While RACD is an
intuitively appealing approach to identify
infections, we know of no studies that assess
its impact on transmission.
Proactive Case Detection
PACD, which involves screening of
high-risk populations, has been used
extensively to reduce transmission in
countries such as Taiwan [25], China
[26] and Brazil [14], targeting all subjects
or febrile individuals only [27] (as was
common during the era of the Global
Malaria Eradication Program in the 1960s
[28,29]). Field and modeling studies sug-
gest that PACD can reduce transmission
when diagnostic tests detect most infec-
tions, with the longest period of reduction
occurring in lower prevalence settings
[21,30,31]. A recent study in Burkina Faso
found no impact of PACD on parasite
prevalence or incidence of clinical episodes
after 12 months of follow up [32]. The low
sensitivity of rapid diagnostic tests (RDT)
to detect all parasitaemic and gametocy-
taemic individuals was given as a possible
explanation for the limited impact on
parasite prevalence.
Considerations for Successful
ACD Implementation
Given the limited evidence for the
effectiveness of ACD, the number of
different options available, and the con-
trasting epidemiology of malaria between
settings, it is highly unlikely that policy
recommendations for one setting apply to
any or all others. If, however, programs
decide that ACD fits within the country’s
strategic plan, they need to consider
several issues in order to maximize the
potential impact of ACD.
Choice of Method
Choosing when and what method of
ACD to implement is critical (Figure 2)
[33]. Neither PACD nor RACD are likely
to be successful if targeted to areas with
highly transient populations. In very low
transmission settings, such as pre-elimina-
tion, elimination, and prevention of rein-
troduction stages, imported parasites are
or will become the main infection source
initiating chains of malaria transmission.
Border screening is one PACD approach
to implement to identify these infections
[34–36]; however, it is costly, labor-
intensive, and misses subjects crossing at
unofficial borders. This strategy may not
be practical and financially feasible in
larger or less well-resourced countries,
particularly those with high volumes of
cross-border movement. Alternatively, in-
dividuals can be targeted by identifying
the networks to which they are affiliated.
For example, if an infection is thought to
be imported, fellow travelers should be
identified, using snowball and time-loca-
tion sampling [37], and then screened and
treated where appropriate.
RACD should only be conducted in
receptive areas where there is potential for
transmission around the residence of the
index case. In these areas, RACD should
take place regardless of a case being
reported as imported or locally transmit-
ted, as imported cases may also lead to
local transmission. RACD is typically best
suited to lower endemic settings because of
the high costs involved of tracing each
case. Where resources are scarce, limiting
RACD to certain high-risk situations, such
as within known foci or in areas with low
coverage of indoor residual spraying (IRS)
and/or insecticide-treated nets (ITN),
could help to streamline operations and
lower costs. Similarly, index households
and immediate neighbors of passively
detected cases should be prioritized. In
very low endemic situations where the risk
of malaria may not be related to place of
domicile but rather is related to population
characteristics such as occupation, RACD
can be employed demographically rather
than geographically, reactively screening
networks of individuals with common risk
factors.
PACD is best suited to moderate
transmission settings where risk is defined
in either space or time, such as areas of
well-known seasonality. In such settings,
campaigns should be conducted during
the dry season, when mosquito densities
are lowest and infections are most clus-
tered, as this timing is likely to have the
greatest impact on transmission [4,21,30].
Targeting
ACD can be guided spatially by risk
maps based on parasite prevalence [5], but
Summary Points
N Active case detection (ACD) is a recommended intervention in low malaria
transmission settings, yet evidence for its effectiveness is sparse.
N The potential of ACD to impact transmission is hampered by the ability of
current field diagnostics to detect very low density infections and continued
importation of parasites, as well as the operational challenges of achieving high
coverage.
N The type of ACD employed should be guided by transmission setting and an
understanding of risk factors.
N Standardized monitoring and evaluation of ACD strategies should be an
integral component of ACD campaigns.
N In light of the current sensitivity of field diagnostic tests, targeted mass drug
administration should be evaluated as an alternative or addition to ACD in low
transmission settings.
Box 1. Hotspots and Hotpops
Hotspots: Geographically discrete household or group of households that
maintain malaria transmission throughout the year at significantly higher rates
than their surroundings.
Hotpops: Demographically discrete groups (populations) that maintain malaria
transmission at higher rates than the surrounding population.
Both hotspots and hotpops seed transmission to the surrounding populations in
receptive areas. Targeting these groups prevents malaria spreading more widely.
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these maps become less reliable in very
low transmission settings as prevalence
approaches 0% [38,39]. Maps or models
based on passive surveillance data may
help to delineate transmission zones [40].
Where the location of hotspots and profile
of hotpops appear to be stable over time
[6], initial rounds of PACD can inform
targeted future rounds of PACD and other
interventions.
A better understanding of risk factors
would allow ACD to be focused on those
individuals at highest risk. Risk factors
can be identified through analysis of
routine data; however, risk assessments
are more accurate when made using case-
control study methods [41], such as are
frequently used for outbreak investiga-
tions [42].
Coverage of Population
Coverage (the proportion of the target
population tested during ACD) is un-
likely to be perfect, and is influenced by
the accuracy of the maps used to guide
operations, the availability of resources,
and the mobility and willingness of
populations to be tested. To maximize
coverage, programs should screen com-
munities at times when people are at
home, record who is missed, and return
to improve coverage where possible.
Establishing the number of people
missed and their demographic charac-
teristics is important to ensure that those
at highest risk of malaria infection are
not missed.
Community involvement is likely to
be key to achieving high coverage. In
Peru, community volunteers perform
weekly house-to-house visits to allow
screening and treatment of confirmed
infections [43]. The use of local volun-
teers may also improve coverage
amongst individuals who are away from
the home during the daytime and may
be missed by conventional programmat-
ic ACD.
Choice of Intervention
A key component of any ACD cam-
paign is the intervention that is imple-
mented following the detection of a case.
Treatment of P. falciparum with artemisinin
combination therapies (ACT) alone will
hinder the development of clinical malaria
and can kill immature gametocytes, re-
ducing the probability of onward trans-
mission to mosquitoes [44–46], but it may
not be sufficient to prevent transmission
shortly after treatment [47]. Integrating a
treatment drug that acts against mature
gametocytes, such as an 8-aminoquinoline,
has the potential to further reduce trans-
mission [48,49]. Recently, WHO changed
its recommendation on the use of prima-
quine for P. falciparum (Box 3) [50].
In addition to drug treatment, other
interventions, such as targeted vector
Figure 1. Microepidemiology of malaria in villages of varying transmission setting. In moderate/high transmission settings (A), hotspots
coalesce to form a more homogeneous pattern. In lower transmission settings (B), risk becomes increasingly spatially discrete, with single households
or small groups of households experiencing higher exposure. In very low transmission settings (C), risk shifts to individual households or, where
transmission is occurring outside the house/village, to individuals.
doi:10.1371/journal.pmed.1001467.g001
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control, may improve the impact of ACD
[21]. Establishing the optimal vector
control method should be based on local
epidemiology, because long-lasting insec-
ticidal nets (LLIN) and IRS are unlikely to
be successful where transmission occurs
outside the house or is related to occupa-
tion. In such settings, larval source man-
agement, personal protective measures
such as repellent, insecticide-treated cloth-
ing, and insecticide treated hammock nets
should be used where appropriate [51–
53].
Impact and Effectiveness
Mathematical modeling studies sup-
port the idea that PACD using ACT
reduces transmission. However, results
from recent field studies are inconclu-
sive, with Sutcliffe et al. showing an
impact on transmission and Tiono et al.
Figure 2. Illustration of hotpops (hot populations). While infection may be detected in individuals at their home, they acquire their infections
elsewhere. For example, individuals may be exposed to infectious mosquitoes when working in particular forests overnight (e.g., rubber tappers);
when camping in the forest due to occupation (e.g., loggers, miners, and military personnel); or in their place of origin (migrant laborers). These
demographic groups are at high risk of infection and can seed malaria transmission to others in receptive areas.
doi:10.1371/journal.pmed.1001467.g002
Box 2. WHO Definition of Active Case Detection
‘The detection by health workers of malaria infections at community and
household level in population groups that are considered to be at high risk.
Active case detection can be conducted as fever screening followed by
parasitological examination of all febrile patients or as parasitological examina-
tion of the target population without prior screening.’ [12]
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showing no impact [31,32]. For RACD,
we are not aware of any studies
measuring the impact on transmission.
Despite this dearth of evidence, both
strategies are implemented widely.
Thus, there is an urgent need to develop
and install monitoring and evaluation
tools, using standardized indicators to
assess processes and impact (Table 1). In
low-to-moderate transmission settings,
such impact evaluation may be possible,
as done by Sutcliffe et al. (2012), using
sequential cross- sectional surveys to
assess changes in infection prevalence.
Use of sensitive molecular methods is
preferable over RDT for such an
evaluation, to allow detection of a larger
proportion of asexual and sexual para-
site stages. In elimination settings, how-
ever, such methods are inappropriate
due to the paucity of positives. Evalua-
tion must rely on other transmission
metrics, such as incidence and serolog-
ical responses. Randomizing campaigns
to areas, or adopting a step wedge
design, should be used to help control
for the effect of possible confounding
factors, such as climate. In addition to
evaluating epidemiological indicators,
programs can evaluate their operational
efficiency using simple, key indicators of
programmatic performance; e.g., the
proportion of cases recorded and inves-
tigated within 7 days of presentation of
the index case for evaluating RACD.
Similarly, assuming global positioning
system (GPS) coordinates are collected,
the proportion of households covered
for both RACD and PACD can be
estimated using freely available satellite
imagery [54]. Costs of campaigns
Table 1. Characteristics of Reactive and Proactive Case Detection.
Characteristic Reactive Proactive
Definition Screening and treatment for household members
and neighbors of a passively detected index case
Screening and treatment in communities and
among specific high risk groups without the trigger
of a passively detected index case
Advantages Allows screening to be targeted in space and time
Participation more likely as subjects more willing
to participate when index case is known to them
Able to target screening to high-risk groups
Able to support identification of asymptomatic
hotspots
Able to target populations with poor access to
healthcare
Disadvantages Requires team on-call year round unless employed
seasonally
May miss populations with low or no access to
health care
Community campaigns large
Participation may be limited due to perception of
low risk in low transmission sites
Recommendations for epidemiological/impact
evaluation
Compare routine clinical incidence of locally
acquired cases in implementation and control
areas
Compare routine clinical incidence of locally
acquired cases (no travel within 4 weeks) in
implementation and control areas (low
transmission)
Compare infection prevalence within different
radii around each index case to help inform
optimal screening radius
Compare change in infection prevalence between
implementation and control areas using sequential
cross-sectional surveys with sensitive molecular
methods (moderate transmission)
Recommendations for operational/process evaluation Cost of implementation, proportion of cases
recorded and investigated within 7 days of
index case presentation, proportion of individuals
screened within screening radius, mean
person/time required to: (a) screen one
individual; (b) identify one infection.
Cost of implementation, proportion of individuals
screened, mean person/time required to: (a) screen
one individual; (b) identify one infection.
Compare performance of diagnostic test against molecular-based gold standard
Challenges and research priorities N Impact on transmission unknown
N Optimal target population not established
N Optimal timing and frequency not established
N Development of a highly sensitive and convenient diagnostic method
N Coverage of screening needed to affect transmission not known
N Methods to gain access to hard-to-reach populations required
N Usefulness for P. vivax unclear
N Cost-effectiveness studies required
doi:10.1371/journal.pmed.1001467.t001
Box 3. WHO Primaquine Recommendation
In areas threatened by artemisinin resistance where single dose primaquine as a
gametocytocide for P. falciparum malaria is not being implemented, and
elimination areas which have not yet adopted primaquine as a gametocytocide
for falciparum malaria, a single 0.25 mg base/kg primaquine dose is recom-
mended. This should be given to all patients with parasitologically-confirmed
falciparum malaria on the first day of ACT treatment regardless of G6PD status,
except for pregnant women and infants ,1 year of age.
ACT, artemisinin combination therapy; G6PD, glucose-6-phosphate-dehydroge-
nase.
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should be recorded to allow assessment
of cost-effectiveness to enable compari-
son with other interventions and to
assess long-term financial feasibility.
P. vivax
While there are commonalities with
ACD for P. falciparum, ACD for P. vivax
control and elimination faces unique
challenges. Firstly, P. vivax infections tend
to be maintained at low parasite densities
[55]. Secondly, P. falciparum-specific
RDT used in many countries are unable
to detect other Plasmodium species [56,57]
and newer RDT that detect non-falci-
parum species still need evaluation in the
field [58]. Thirdly, P. vivax (and P. ovale)
has dormant liver stages (hypnozoites),
which currently are impossible to detect.
ACD for P. vivax may, therefore, require
several rounds to capture individuals
when their infections relapse, often
without causing clinical symptoms.
Sero-diagnosis, whereby anyone who is
sero-positive is assumed to be infected
and is treated [59], is one potential
approach to overcome this challenge. A
second approach is mass drug adminis-
tration (MDA). However, treatment of
the liver stage infection at present
requires treatment with primaquine, an
8-aminoquinoline that can produce acute
haemolytic anemia in individuals who
are glucose-6-phosphate-dehydrogenase
(G6PD) deficient [60]. Tafenoquine, a
new 8-aminoquinoline under develop-
ment, induces a similar effect; studies
are ongoing to identify safe and effective
dosages that demonstrate efficacy. Until
such dosages are determined, adminis-
tration of primaquine or tafenoquine
requires initial testing for G6PD defi-
ciency. While tests for G6PD deficiency
are available, more sensitive and inex-
pensive point of care tests for G6PD
deficiency are needed [61].
Screening Test Sensitivity and
Mass Drug Administration
RDT and microscopy are the diagnostic
method of choice for ACD [23,31,62].
With increased use of more sensitive
molecular methods, it is becoming clear
that, contrary to traditional thought, the
proportion of sub-patent infections (below
the density detectable by microscopy and
RDT) appears to increase with decreasing
transmission [63,64]. Due to residual
levels of immunity, the proportion of
infections that are sub-patent may also
be particularly high in areas that have
experienced recent declines in transmis-
sion. While patent asymptomatic infection
may be responsible for the majority of
transmission in many settings, because of a
positive correlation between sexual para-
site density and transmission to mosqui-
toes, sub-patent infections in very low
transmission settings are estimated to
Figure 3. Potential application of different active surveillance and mass drug administration approaches to reduce transmission.
Due to the resource requirements of tracing cases back to their home, reaction case detection (RACD) is best suited to lower transmission settings.
Similarly, to avoid large amounts of unnecessary treatments, mass drug administration (MDA) is better suited to higher transmission settings; lower
transmission areas may benefit from a more targeted approach. Where risk factors are well defined, proactive case detection (PACD) and MDA are
good options. RACD and targeted mass drug administration (tMDA) are useful where risk factors are not well defined, as passively or actively
detected cases can be used to identify at-risk populations. Where the proportion of asymptomatic infections is high, passive surveillance does not
suffice and additional active surveillance and presumptive treatment are required. Where the proportion of sub-patent infections is high, active
surveillance using current diagnostics is less likely to impact transmission, and presumptive treatment (MDA or tMDA) should therefore be
considered.
doi:10.1371/journal.pmed.1001467.g003
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make up 20 to 50% of all human-to-
mosquito transmissions [64].
Detecting sub-patent infections requires
sensitive molecular diagnostic methods,
such as polymerase chain reaction (PCR)
or loop-attenuated isothermal amplifica-
tion (LAMP) [46,63,65]. At present, the
use of PCR and LAMP for ACD is
impractical because of their cost, infra-
structure requirements, and long turn-
around times. Although the use of molec-
ular methods will certainly increase the
proportion of the true reservoir of infec-
tions that is detectable, very low density
infections may still be missed. While more
sensitive field diagnostics are being devel-
oped, PCR and LAMP can be used to
quality assure RDT and microscopy and
to identify infections missed by other
methods [66,67].
Serology, or the detection of antimalar-
ial antibodies, cannot be used to identify
who has current infection during ACD.
However, when the prevalence of infec-
tion detected by RDT or PCR is low,
evidence of recent or past infection can be
used to identify high-risk geographic
regions or populations, or conversely to
confirm absence of transmission [68–70].
Sero-diagnosis may also serve as a surro-
gate for potential liver carriage of P. vivax
[59].
An alternative to ACD, which over-
comes the issue of missed infections, is
MDA to populations with pre-defined risk
factors, such as all individuals within
known hotspots or migrant workers arriv-
ing from malaria endemic countries
[71,72] (Figure 3). Where risk factors are
not well defined, an effective approach
might be targeted MDA (tMDA) to
households or groups of households iden-
tified via passively or actively detected
cases. A similar household treatment
approach has been suggested for schisto-
somiasis [73,74]. Such an approach war-
rants investigation in the context of
malaria control, although the correct drug
combination needs to be explored. At a
stage where the number of programs
implementing ACD is increasing, further
rigorous evaluation of ACD, and compar-
ison with MDA with regard to effective-
ness, cost-effectiveness, and operational
feasibility, is critical.
Conclusions
ACD strategies are adopted by a
number of malaria control programs
worldwide. Despite their popularity, the
different approaches used are poorly
defined and evaluated, and the factors
that affect their effectiveness are not well
understood. Key challenges include miss-
ing infections due to inadequately sensitive
diagnostics, missing individuals due to low
coverage of those most at risk, dealing with
imported parasites, and diagnostic and
therapeutic difficulties of non-falciparum
parasites. Given these challenges, pro-
grams implementing ACD need to con-
sider several factors. The type of ACD
employed should be guided by transmis-
sion setting; RACD is better suited to low
transmission settings, whereas PACD is
better suited to moderate/low transmis-
sion settings. To maximize its impact,
ACD should be targeted based on geo-
graphic and demographic risk. Where
these risks are not well known, RACD
may be a more appropriate option over
PACD. Achieving high coverage should
be a priority and requires operational
methods, such as involving community
volunteers. Once infections are identified,
appropriate interventions, including drug
treatment and targeted vector control,
should be implemented. Finally, the de-
velopment and installation of standardized
tools to monitor and evaluate ACD
strategies is essential to establish the cost-
effectiveness of prolonged campaigns and
to ensure the most efficient distribution of
limited resources. More research on the
relative cost-effectiveness and operational
feasibility of ACD strategies as well as
MDA is needed to enable the development
of evidence-based guidance.
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